In the year 2021, the universal de?nition and classi­?cation of heart failure (HF) was published that de?nes HF as a clinical syndrome with symptoms and/or signs caused by a cardiac abnormality and corroborated by elevated natriuretic peptide levels or objective evidence of cardiogenic congestion. This de?nition and the classi?cation of HF with reduced ejection fraction (HFrEF), mildly reduced, and HF with pre-served ejection fraction (HFpEF) is consistent with the 2021 ESC Guidelines on HF. Among several other new recommendations, these guidelines give a Class I indication for the use of the sodium-glucose co-transporter 2 (SGLT2) inhibitors dapagli?ozin and empagli?ozin in HFrEF patients. As the ?rst evidence-based treatment for HFpEF, in the EMPEROR-Preserved trial, empagli?ozin reduced the composite endpoint of cardiovascular death and HF hospitalizations. Several reports in 2021 have provided novel and detailed analyses of device and medical therapy in HF, especially regarding sacubitril/valsartan, SGLT2 inhibitors, mineralocorticoid receptor antagonists, ferric carboxymal-tose, soluble guanylate cyclase activators, and cardiac myosin activators. In patients hospitalized with COVID-19, acute HF and myocardial injury is quite frequent, whereas myocarditis and long-term damage to the heart are rather uncommon. Kulcsszavak: Heart failure, Epidemiology, Imaging, Biomarkers, Pharmacottherapy, Artifical inteligence, SGLT-2 inhibitor, Angiotensin receptor-neprilysin inhibitors, Activators of soluble guanylate cyclase, Device therapy